Virtual Library

Start Your Search

Antonieta Salud



Author of

  • +

    EP1.01 - Advanced NSCLC (ID 150)

    • Event: WCLC 2019
    • Type: E-Poster Viewing in the Exhibit Hall
    • Track: Advanced NSCLC
    • Presentations: 1
    • Now Available
    • Moderators:
    • Coordinates: 9/08/2019, 08:00 - 18:00, Exhibit Hall
    • +

      EP1.01-92 - Effectiveness of Second-Line Treatment with Nintedanib + Docetaxel (ND) in Patients with Metastatic Lung Adenocarcinoma (Now Available) (ID 1815)

      08:00 - 18:00  |  Author(s): Antonieta Salud

      • Abstract
      • Slides

      Background

      Nintedanib is an oral angiokinase inhibitor directed against VEGFR 3, FGFR 1-3, and PDGFR alpha and beta. It is approved by the European Medicines Agency in combination with docetaxel for the treatment of metastatic lung adenocarcinoma previously treated with platinum-doublet chemotherapy. Given the efficacy of checkpoint inhibitors in the second-line treatment of advanced lung cancer, we evaluated the outcomes of ND in this setting

      Method

      Patients diagnosed with advanced lung cancer between July 2015 to October 2017 at the University Hospital Arnau de Vilanova (Lleida, Spain) and treated with ND were included. The clinical history, tumor pathology, tumor biologic characteristics, treatments prior and posterior to ND were reviewed. Statistical analysis was realized using IBM SPSS Statistics 23.0 software. Overall survival (OS) was calculated by Kaplan-Meier curve, determining a median OS with 95% confidence interval and estimated mortality rates during each year of follow-up

      Result

      Thirteen of 357 patients with advanced lung cancer during the time period specified were treated with ND and included in the analysis. Median follow-up was 14.4 months (range: 7.3 – 41.2 months). Median age at diagnosis was 62.1 years (range: 46-73 years). Never-smokers comprised 15.4% of the patients, ex-smokers 46.2% and active smokers 38.5%. Bone metastases were present in 23.1% of patients, while 15.4% and 15.3% had central nervous system and hepatic metastases, respectively. The majority, 69.2%, received a platinum-doublet first-line and 46.2% received pemetrexed maintenance. The median number of ND cycles was four. Responses to ND were 53.8% partial response (PR), 23.2% stable disease (SD), and 23% progressive disease, with a disease control rate (DCR) of 77%. 53.8% of patients continued with nintedanib maintenance with the following responses: 43% PR, 14.3% SD, and 42.7% progressive disease (DCR 57.3%). There were no grade 2 or greater toxicities in the nintedanib maintenance group. Fifty-four percent of ND patients received third-line therapy: 50% atezolizumab, 16.7% carboplatin + vinorelbine, 16.7% nivolumab, and 16.7% oral vinorelbine. Eleven percent of patients received fourth-line therapy. Median OS was 14.4 months (CI 95%: 11.7 – 17.1 months). OS rates at 2 and 3 years were 69.2% (CI 95%: 44,1% - 94,3%) and 23.1% (CI 95%: 0,2 - 46%), respectively

      Conclusion

      ND is an effective second-line treatment for patients with advanced lung adenocarcinoma. In this descriptive analysis, the median OS associated with ND was superior to the results of Lume-Lung 1 and Checkmate 057, although the study is limited by sample size

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.

  • +

    P2.16 - Treatment in the Real World - Support, Survivorship, Systems Research (ID 187)

    • Event: WCLC 2019
    • Type: Poster Viewing in the Exhibit Hall
    • Track: Treatment in the Real World - Support, Survivorship, Systems Research
    • Presentations: 1
    • Now Available
    • Moderators:
    • Coordinates: 9/09/2019, 10:15 - 18:15, Exhibit Hall
    • +

      P2.16-29 - Lung Cancer in Lleida: An Epidemiologic Study (Now Available) (ID 1838)

      10:15 - 18:15  |  Author(s): Antonieta Salud

      • Abstract
      • Slides

      Background

      According to GLOBOCAN, in 2018 lung cancer was associated with the greatest incidence and mortality attributable to cancer worldwide: 27.9 cases/100,000 habitants and 23.5 cases/100,000 habitants, respectively. In Spain, lung cancer is the fourth most frequent cancer but the first cause of cancer mortality in the country. We have undertaken this study to compare the epidemiologic data for lung cancer in our Spanish provincial population with those worldwide and nationwide

      Method

      This was an observational, retrospective study. It included all patients with lung cancer in the Lleida province of Catalonia, Spain in a period of 6 years, from January 2011 to December 2016. Data taken from electronic medical records included variables such as sex, age of diagnosis, smoking history, histology, stage, and oncologic treatments, among others. Incidence, prevalence, survival and mortality rates were determined, as well as the main clinical characteristics of the cohort

      Result

      Seven hundred eighty-two patients with a diagnosis of lung cancer between January 2011 and December 2016 were included. Median follow-up was 11.7 months. Men comprised 78.6% of the cohort. The median age at diagnosis was 66.6 years. More than half of the patients (53.2%) smoked at the time of diagnosis. The majority were adenocarcinomas (44.1%), with 33.2% squamous cell carcinomas, and 12.1% small cell carcinomas. EGFR testing was performed in 300 patients. 18.7% were positive for a mutation, of which 69.7% were exon 19 insertions. At diagnosis, 52.3% of cases were stage IV, 25.3% stage III, 7.3% stage II, and 14.5% stage I. The average annual incidence rate was 37 cases/100,000 habitants. The median overall survival (OS) was 12.3 months (95% CI: 10.7-13.8). The OS at 1 year was 50.8% (95% CI: 47.3-54.3) and at 5 years was 13.7% (95% CI: 10.2-17.2). The estimated mortality rates were 49.2% in the first year and 86.3% at 5 years

      Conclusion

      In the Lleida province of Spain, the incidence and mortality associated with lung cancer are greater than global rates but lower than those of Spain as a whole. Lung cancer survival at 5 years is greater than countrywide statistics. The heathier lifestyle and rural geography may favor the lower incidence of lung cancer in Lleida compared with the rest of Spain

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.